Evaluating the effectiveness and safety of JAK inhibitors for alopecia areata
Efficacy and Safety of JAK Inhibitors in Patients With Alopecia Areata: a Single-center, Real-world Study
This study is testing how well and safely JAK inhibitors work for kids and teens with alopecia areata who have been using them for at least three months.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 2 Years to 80 Years |
| Sex | All |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University Academic / other |
| Drugs / interventions | tofacitinib, baricitinib, ritlecitinib, abrocitinib, upadacitinib, ifidancitinib |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT06573593 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the real-world effectiveness and safety of various Janus Kinase inhibitors (JAKi) in patients with alopecia areata (AA). It will gather data on patients aged 2 to 18 who have been treated with JAKi for over three months, focusing on their baseline disease characteristics and profiles that indicate suitability for JAKi therapy. The study will provide valuable clinical evidence to help clinicians and patients make informed decisions regarding individualized treatment plans for AA.
Who should consider this trial
Good fit: Ideal candidates for this study are patients aged 2 to 18 years diagnosed with alopecia areata and treated with JAK inhibitors for more than three months.
Not a fit: Patients who have received hair implants or have other forms of alopecia or diseases that induce alopecia may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide critical insights into the most effective JAK inhibitors for treating alopecia areata, leading to better patient outcomes.
How similar studies have performed: While the use of JAK inhibitors in alopecia areata is a relatively new approach, preliminary studies have shown promising results, indicating potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with alopecia areata between 2 to 18 years old * Patients diagnosed with alopecia areata according to AA guideline * AA Patients treated with JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib for more than 3 months Exclusion Criteria: * Patients had previously received hair implants * Other alopecia * Other diseases may induce alopecia including psoriasis, lichen planus, et al. * Unable to estimate SALT score at baseline or at follow-up * Patients are participating in other clinical trials
Where this trial is running
Hangzhou, Zhejiang
- Second Affiliated Hospital, School of Medicine, Zhejiang University, China — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Principal investigator: Xianjie Wu, Ph.D — Second Affiliated Hospital, School of Medicine, Zhejiang University
- Study coordinator: Ru Dai, MD
- Email: dairu@zju.edu.cn
- Phone: 15982215914
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.